Related Experiment Video
Updated: Jun 3, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Clinical and echocardiographic predictors of nonresponse to cardiac resynchronization therapy
Miriam Shanks1, Victoria Delgado, Arnold C T Ng
1Department of Cardiology, Leiden University Medical Center, The Netherlands.
Insights
Up to 44% of heart failure patients do not respond to cardiac resynchronization therapy (CRT). Key predictors of nonresponse include ischemic heart failure, reduced baseline walk distance, less left ventricular dyssynchrony, and anterior LV lead placement.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Cardiac resynchronization therapy (CRT) is a treatment for heart failure (HF).
- A significant percentage of patients (30-40%) do not respond to CRT.
- Identifying nonresponse predictors is crucial for optimizing HF treatment.
Purpose of the Study:
- To identify clinical and echocardiographic factors associated with nonresponse to CRT.
- To evaluate determinants of CRT efficacy in advanced HF patients.
Main Methods:
- 581 advanced HF patients undergoing CRT implantation were assessed.
- Clinical and echocardiographic data were collected at baseline and 6 months.
- Nonresponse was defined by lack of functional improvement, HF-related mortality, or insufficient LV volume reduction.
Main Results:
- 44% of patients (254/581) were nonresponders at 6 months.
- Nonresponders showed higher rates of male sex, ischemic cardiomyopathy, worse NYHA class, and shorter 6-minute walk distance.
- Less baseline left ventricular (LV) dyssynchrony and anterior LV lead position were also associated with nonresponse.
Conclusions:
- Ischemic HF etiology is a significant predictor of CRT nonresponse.
- Shorter baseline 6-minute walk distance and less LV dyssynchrony independently predict nonresponse.
- Anterior LV lead position is also an independent determinant of CRT nonresponse.
Background:
Lack of response to cardiac resynchronization therapy (CRT) ranges between 30% to 40% of heart failure (HF) patients. The present study aimed to evaluate the clinical and echocardiographic determinants of nonresponse to CRT.
Methods:
A total of 581 patients (66.4 ± 10.0 years, 77.9% male) with advanced HF scheduled for CRT implantation were included. Clinical and echocardiographic evaluations were performed at baseline and 6 months of follow-up. Nonresponse was defined as no improvement in the New York Heart Association functional class, death from worsening HF or heart transplantation, and <15% reduction in left ventricular (LV) end-systolic volume.
Results:
At 6 months of follow-up, 254 patients (44%) did not respond to CRT. The nonresponders were more frequently male (81.9% vs 74.3%, P = .030) and had ischemic cardiomyopathy (69.7% vs 53.2%, P < .001), shorter QRS duration (150.6 ± 29.9 milliseconds vs 156.0 ± 32.5 milliseconds, P = .041), worse New York Heart Association functional class (2.8 ± 0.6 vs 2.7 ± 0.6, P = .008) and shorter 6-minute walk distance (297.9 ± 110.7 m vs 331.8 ± 112.6 m, P = .001), larger left atrial volumes (44.9 ± 16.9 mL/m(2) vs 40.9 ± 17.6 mL/m(2), P = .006), less baseline LV dyssynchrony (56.2 ± 41.3 milliseconds vs 69.1 ± 39.9 milliseconds, P < .001), and, more frequently, anterior LV lead position (12.4% vs 4.0%, P = .007). At multivariate analysis, only the ischemic etiology of HF (odds ratio [OR] 2.264, P = .005), shorter 6-minute walk distance at baseline (OR 0.998, P = .030), less baseline LV dyssynchrony (OR 0.989, P < .001), and anterior LV lead position (OR 3.713, P < .010) remained independent predictors of nonresponse to CRT.
Conclusions:
Ischemic etiology of HF, shorter baseline 6-minute walk distance, less baseline LV dyssynchrony, and anterior LV lead position are independent determinants of nonresponse to CRT.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Acute Coronary Syndrome III: Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Heart Failure III: Clinical Manifestations
Heart Failure IV: Classification and Diagnostic Evaluation
